Comparison of pemetrexed plus cisplatin with other first-line doublets in advanced non-small cell lung cancer (NSCLC): A combined analysis of three phase III trials

被引：0
|
作者：
Treat, J.
Scagliotti, G.
Peng, G.
Monberg, M. J.
Obasaju, C. K.
机构：
[1] Eli Lilly & Co, Indianapolis, IN 46285 USA
[2] Univ Turin, S Luigi Hosp, Dept Clin & Biol Sci, Turin, Italy
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2011年 / 29卷 / 15期
关键词：
D O I：
10.1200/jco.2011.29.15_suppl.e18004
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e18004
引用
下载
收藏
页数：1
相关论文
共 50 条
  • [1] COMPARISON OF PEMETREXED PLUS CISPLATIN WITH OTHER FIRST-LINE DOUBLETS IN ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC): A COMBINED ANALYSIS OF THREE PHASE 3 TRIALS
    Treat, Joseph
    Scagliotti, Giorgio
    Peng, Guangbin
    Pohl, Gerhardt
    Obasaju, Coleman
    JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S415 - S416
  • [2] Comparison of pemetrexed plus cisplatin with other first-line doublets in advanced non-small cell lung cancer (NSCLC): A combined analysis of three phase 3 trials
    Treat, Joseph
    Scagliotti, Giorgio V.
    Peng, Guangbin
    Monberg, Matthew J.
    Obasaju, Coleman K.
    Socinski, Mark A.
    LUNG CANCER, 2012, 76 (02) : 222 - 227
  • [3] FIRST LINE CHEMOTHERAPY WITH PEMETREXED PLUS CISPLATIN IN ADVANCED NONSQUAMOUS NON-SMALL CELL LUNG CANCER (NSCLC): A COMPARISON OF TWO PHASE III TRIALS
    Scagliotti, Giorgio
    Gridelli, Cesare
    De Marinis, Filippo
    Thomas, Michael
    Dedui, Mircea
    Pujol, Jean-Louis
    Manegold, Christian
    Melemed, Symantha
    John, William
    Zimmermann, Annamaria H.
    Chouaki, Nadia
    Melemed, Allen
    Visseren-Grul, Carla
    Paz Ares, Luis
    JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S1160 - S1161
  • [4] THE BUDGETARY IMPACT OF PEMETREXED PLUS CISPLATIN AS FIRST-LINE THERAPY FOR ADVANCED NONSQUAMOUS NON-SMALL CELL LUNG CANCER (NSCLC)
    Wielage, R. C.
    Muehlenbein, C. E.
    Liepa, A. M.
    Babineaux, S. M.
    Klein, R. W.
    Schwartzberg, L. S.
    VALUE IN HEALTH, 2009, 12 (03) : A39 - A39
  • [5] PALLIATIVE RADIATION DURING PEMETREXED PLUS CISPLATIN FIRST-LINE TREATMENT FOR ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC): PATIENT SAFETY IN THE JMDB AND PARAMOUNT TRIALS
    Scagliotti, G. V.
    Gridelli, C.
    de Marinis, F.
    Biesma, B.
    Reck, M.
    San Antonio, B.
    Zimmermann, A. H.
    Visseren-Grul, C.
    Chouaki, N.
    Paz-Ares, L.
    JOURNAL OF THORACIC ONCOLOGY, 2014, 9 (04) : S45 - S45
  • [6] Cost-Utility Analysis of First-Line Pemetrexed Plus Cisplatin in Non-Small Cell Lung Cancer in Thailand
    Permsuwan, Unchalee
    Thongprasert, Sumitra
    Sirichanchuen, Buntitabhon
    VALUE IN HEALTH REGIONAL ISSUES, 2020, 21 : 9 - 16
  • [7] Cost-Effectiveness of Pemetrexed Plus Cisplatin as First-Line Therapy for Advanced Nonsquamous Non-small Cell Lung Cancer
    Klein, Robert
    Muehlenbein, Catherine
    Liepa, Astra M.
    Babineaux, Steve
    Wielage, Ron
    Schwartzberg, Lee
    JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (11) : 1404 - 1414
  • [8] First-line cisplatin plus pemetrexed therapy for selected patients with advanced nonsquamous non-small cell lung cancer.
    Nakashima, Kazuhisa
    Murakami, Haruyasu
    Imai, Hisao
    Ono, Akira
    Taira, Tetsuhiko
    Kenmotsu, Hirotsugu
    Naito, Tateaki
    Endo, Masahiro
    Takahashi, Toshiaki
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [9] Favorable benefit to risk profile for pemetrexed plus cisplatin versus gemcitabine plus cisplatin in a large phase III study of first-line therapy in advanced non-small cell lung cancer
    Scaqliotti, G.
    Park, K.
    Patil, S.
    Rolski, J.
    Gorksel, T.
    Gans, S. J. M.
    Martins, R.
    Visseren-Grul, C.
    Peterson, P.
    EJC SUPPLEMENTS, 2007, 5 (04): : 363 - 363
  • [10] EFFECTIVENESS OF FIRST-LINE PEMETREXED PLUS PLATINUM FOR ADVANCED NONSQUAMOUS NON-SMALL CELL LUNG CANCER
    Brandao, M. D. R. A.
    Luis, M. S.
    Amaral, N. C.
    Cassiano Neves, M.
    Camacho, C.
    Rodrigues, A. C.
    Pousa, I.
    Oliveira, J.
    Azevedo, I.
    ANNALS OF ONCOLOGY, 2015, 26
12345